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A B S T R A C T   
Fluid sampling from the gastrointestinal (GI) tract has been applied as a valuable tool to gain more insight into 
the fluids present in the human GI tract and to explore the dynamic interplay of drug release, dissolution, 
precipitation and absorption after drug product administration to healthy subjects. In the last twenty years, 
collaborative initiatives have led to a plethora of clinical aspiration studies that aimed to unravel the luminal 
drug behavior of an orally administered drug product. The obtained drug concentration-time profiles from 
different segments in the GI tract were a valuable source of information to optimize and/or validate predictive in 
vitro and in silico tools, frequently applied in the non-clinical stage of drug product development. Sampling 
techniques are presently not only being considered as a stand-alone technique but are also used in combination 
with other in vivo techniques (e.g., gastric motility recording, magnetic resonance imaging (MRI)). By doing so, 
various physiological variables can be mapped simultaneously and evaluated for their impact on luminal drug 
and formulation behavior. This comprehensive review aims to describe the history, challenges and opportunities 
of the aspiration technique with a specific focus on how this technique can unravel the luminal behavior of drug 
products inside the human GI tract by providing a summary of studies performed over the last 20 years. A section 
‘Best practices’ on how to perform the studies and how to treat the aspirated samples is described. In the con-
clusion, we focus on future perspectives concerning this technique.   
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1. Introduction 
Unraveling the complex gastrointestinal (GI) processes that a drug 
product needs to face after oral administration remains extremely 
challenging. However, there are numerous techniques described in the 
literature that can contribute to a better understanding of how GI 
physiology may impact oral drug behavior and vice versa (Hens et al., 
2016c, 2020). Gaining knowledge on how these underlying mechan-
isms influence the systemic exposure of a drug is extremely valuable 
and may explain the differences in fraction absorbed of a drug between- 
and within-subjects. The underlying variables that play a major role in 
determining the fraction absorbed of a drug are subject of interest to be 
implemented in biopredictive in vitro and in silico tools to adequately 
reflect the in vivo behavior of a drug product during the non-clinical 
stage of drug development (Lennernäs et al., 2014). When optimized 
and validated, these models will allow for a more rational selection of 
formulation strategies in the pharmaceutical industry, resulting in time- 
and cost-effective research which is a benefit for pharmaceutical com-
panies. 
The different techniques that are commonly used in daily practice to 
investigate the luminal behavior of a drug can be classified into two 
categories: invasive and non-invasive methodologies. It should be noted 
that some of these methodologies are more historical than operational; 
however, they have been of paramount importance for innovations in 
drug and formulation development; besides, they have created the basis 
for several novel applications, leading to an in-depth comprehension of 
different GI variables such as gastric emptying (e.g., scintigraphy, tracer 
assessment), motility (e.g., gastric/small intestinal/colonic mano-
metry), GI volume changes (e.g., MRI), temperature (e.g., telemetric 
capsules) and GI pH (e.g., intraluminal sampling technique, telemetric 
capsules) (Diaz Tartera et al., 2017; Hens et al., 2016c; Näslund et al., 
2000). Based on pioneer work of Armstrong et al. and Spiller et al., 
novel insights were created to explore luminal concentrations of an 
orally administered drug product in combination with the measurement 
of surrounding physiology as, for example, the influence of motility on 
intestinal absorption (Armstrong et al., 1993; Braeckmans et al., 2020;  
Farmer et al., 2018; Hens et al., 2017, 2020; Spiller et al., 1988;  
Van Den Abeele et al., 2017b). 
Direct measurement of luminal concentrations of a drug after oral 
administration of the drug product is a valuable tool to assess the lu-
minal behavior of a drug product in the human GI tract. Moreover, the 
observed differences between subjects can be an important indicator to 
explain inter-subject differences in systemic exposure, where the un-
derlying GI variability can be a potential source of bio-inequivalence. 
Measuring luminal and systemic concentrations simultaneously creates 
a valuable data source concerning optimization of in vitro and in silico 
models; both approaches can be directly validated with GI concentra-
tion-time profiles; in case of in silico tools, predicted systemic con-
centration-time profiles can be directly compared with the observed 
systemic exposure in humans. However, caution should be taken as the 
assumption of well stirred compartment in systemic sampling may not 
apply in sampling from the GI lumen (Mudie et al., 2014; Murray et al., 
2017; Schiller et al., 2005). 
Throughout the years, the aspiration technique has demonstrated - 
for various drug formulations - how the drug formulation behaves in a 
complex GI environment and, consequently, what the potential impact 
of this environment may be on the obtained luminal and systemic 
concentration-time profiles of the drug. Additionally, the aspirated 
fluids have been characterized for their specific content (e.g., bile salts, 
phospholipids, lipid degradation products, pH and enzymatic activity) 
and the effect of these variables on luminal drug concentrations were 
thoroughly explored (Lindahl et al., 1997; Riethorst et al., 2018; 2016b,  
2016a). A wide variety of applications has been described related to this 
technique, dating back from the late 19th century when acidic content 
from the more easily accessible stomach was aspirated (Lewis, 1999). 
Currently, the intestinal sampling technique allows aspirating fluids in 
more distal parts of the GI tract, which enabled the determination of the 
permeability of the membrane for a series of compounds by the Loc-I- 
GutⓇ technique, thoroughly explored in the nineties (Amidon et al., 
1995; Lennernäs, 1998, 1997). From 2000 onwards, the sampling 
technique was further explored to unravel the formulation behavior for 
numerous compounds that are commercially available on the market 
(Brouwers and Augustijns, 2014; Butler et al., 2019). An intra-intestinal 
infusion technique to administer drugs - with narrow therapeutic index 
and with an absorption process mainly occurring in the small intestine 
(absorption windows) - has been developed and approved, as seen for 
levodopa (used in the later stage of Parkinson's disease) (Nyholm et al., 
2012, 2003). 
This review describes the history, challenges and opportunities of 
the aspiration technique with a specific focus on how this technique can 
unravel the luminal behavior of drug products inside the human GI 
tract by providing a comprehensive summary of studies performed over 
the last 20 years. A section ‘Best practices’ on how to perform the 
studies and how to treat the aspirated samples is included. In conclu-
sion, the future perspectives of this technique are addressed. 
2. History of the sampling technique 
Although GI sampling is perceived as a relatively new technique to 
investigate drug and formulation behavior in the human GI tract, nu-
merous manuscripts reporting on GI intubation can be found in the 
‘older’ literature. The sampling of GI fluids for drug absorption research 
has been adopted by pharmaceutical scientists from (digestive) phy-
siology studies, of which the early literature has already been reviewed 
by Sladen in 1968 (Sladen, 1968). Indeed, GI intubation has served 
many purposes, including the characterization of GI physiology (e.g., 
pH, motility, digestion), diagnosis (e.g., microbiota studies) and the 
infusion of liquids for diagnostic or therapeutic purposes along the GI 
tract. 
Direct in vivo GI physiological and digestion investigations were 
already initiated in the early 19th century (between 1825 and 1834) 
with the sampling of acidic gastric content. One of the pioneers in direct 
research on GI physiology and digestion was Dr. Beaumont and his 
patient St. Martin. Dr. Beaumont, although situated on the Michigan 
frontier and lacking both formal medical education and scientific 
training, treated a gunshot wound but expected the patient to die from 
his injuries (Tanner, 2000). However, St. Martin survived, but with a 
fistula in his stomach that never fully healed. Most of the direct in vivo 
experiments were conducted, as a blessing in disguise, by tying a piece 
of food to a string and inserting it through the hole (remaining from the 
shotgun) into St. Martin's stomach. At regular time points, Dr. Beau-
mont visually examined gastric digestion by removing and observing 
the remaining food particle (Beaumont, 1838). 
The early GI intubation experiments considered the pylorus as a 
difficult hindrance for access to the small intestine. To the best of our 
knowledge, the first intestinal intubation in humans was described in 
1908 by Scheltema, a pediatrician from the Netherlands 
(Scheltema, 1908). The idea of positioning a tube in the intestinal tract 
came from the observation of a chicken which had swallowed a long 
horsehair, one end protruding from the beak, and the other end from 
the cloacal aperture. During his intubation studies, Scheltema in-
troduced a tube through the nose into the pharynx under local an-
esthesia by insufflation of cocaine powder or a cocaine solution. The 
end of the tube was taken out of the pharynx into the mouth, and a bulb 
was attached to the tube; subsequently, the tube was drawn back into 
the pharynx, while, after the next swallowing movement, the tube 
continued its passive movement along the GI tract, facilitated by the 
presence of the bulbous end. Introducing the tube allowed to locally 
administer fluids. While the tube was in position, Scheltema also col-
lected the contents of the small intestine for examination. The passage 
of the tube from the mouth to the anus was referred to as permeation, 
illustrating that terminology has evolved since then. 
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A major contribution to the field of GI fluid aspiration was made by 
Miller and Abbott who introduced a double-lumen catheter with a 
collapsible balloon at the end of the tube in 1934 (Miller and 
Abbott, 1934), as summarized in 1949 (Miller, 1949). Abbott was in-
vestigating the effect of drugs on the motility in the duodenum using a 
balloon fixed at the end of a duodenal tube. He got frustrated as the 
balloon easily moved down the intestinal tract, impeding him from 
doing the intended measurements. This “slippery” effect of the dis-
tended balloon rapidly turned into an advantage to have a tube moving 
along the GI tract, reaching the ileum in only a few hours. In a next step, 
a second catheter was attached to the first one, immediately after the 
inflatable balloon, allowing the local administration of fluid or the 
collection of intestinal contents. 
Subsequently, a double-lumen was created with one lumen for in-
flating/deflating the balloon to control the progress of the tube, and one 
lumen for the sampling of fluid or injection of liquid. The balloon 
eventually served three purposes: (1) facilitating tube movement along 
the GI tract, (2) creating an intestinal obstruction enabling the collec-
tion of contents above the inflated balloon, and (3) creating the possi-
bility to measure contractions along the intestinal tract. 
Later on, Miller and Abbott further adapted the tube into a triple- 
lumen tube of which two lumens were connected to an inflatable bal-
loon, while the third one was used for fluid collection. The two balloons 
allowed the isolation of a segment of the small intestine for different 
experimental purposes (e.g., studies of secretory and absorptive func-
tions of the intestine, measurement of intra-intestinal pressure changes 
at the level of each balloon) (Abbott and Miller, 1936). 
In 1957, Abbott published a lively story on the selection of volun-
teers for his GI catheter studies. He also commented on the compen-
sation the “tube swallowers” received. When doing a perfusion ex-
periment using a dog, one would have to sacrifice the dog at the end of 
the day. As a dog was worth 2 US $ these days, two dollars a day be-
came the compensation for the volunteers (Abbott, 1957). 
In an important in vivo GI intubation study in humans, performed by 
Hofmann and Borgströn in 1964, the intraluminal phase of dietary fat 
digestion and absorption was investigated in detail (Hofmann and 
Borgström, 1964). Following the oral feeding of a test meal containing 
corn oil, human small intestinal content was collected and investigated 
by GI intubation (Borgström, 1960; Hofmann and Borgström, 1964). 
The direct in vivo study showed that intestinal lipid, during fat diges-
tion, is selectively partitioned between a micellar and an oil phase and 
that intestinal absorption of dietary lipid takes place from a micellar 
solution containing mainly free fatty acid and 2-monoglyceride 
(Borgström, 1960; Hofmann and Borgström, 1964). 
In 1966, Fordtran and Locklear published a study in which gastric 
and small intestinal fluids were collected after the intake of a meal to 
assess their ionic constituents and osmolality (Fordtran and 
Locklear, 1966). The impact of two different meals on the assessment of 
ionic constituents and osmolality was compared, i.e. a 6 oz (170 g) 
sirloin steak-based meal versus a doughnuts-based meal. The volunteers 
were intubated with a single-lumen polyvinyl catheter (1.8 mm internal 
diameter), at the tip of which a 4 cm piece of polyvinyl tubing with 
multiple holes was attached to facilitate the collection of the fluids. In 
separate experiments, they managed to collect gastric, duodenal, je-
junal and ileal fluids. Based on free flow through the catheter by si-
phonage, fluids were collected under oil. 
The intubation technique appeared to be useful to explore site-de-
pendent drug absorption in man. Jobin et al. were one of the first to 
apply the intubation technique in drug absorption studies (Jobin et al., 
1985). They reported in 1985 on the site-dependent absorption of 
metoprolol. Introducing a triple-lumen catheter in the intestine and a 
double-lumen catheter in the stomach, samples were collected from the 
stomach, duodenum and jejunum after perfusion of a homogenized 
meal containing metoprolol (between 93.2 and 95.5 mg) into the sto-
mach. 
This short review of the existing literature illustrates that GI 
intubation studies span over more than a century. In parallel to ad-
vancing the possibilities of local treatment, the intubation approach 
contributed tremendously to our understanding of GI physiology, di-
gestion along the GI tract, and the behavior of drugs and formulations 
in the GI lumen. 
3. Anatomy, physiology and contents characterization of the 
upper and lower GI tract 
3.1. Upper GI tract 
3.1.1. Stomach 
The stomach is a highly complex organ with a critical role in the 
initial steps of digestion before the processed food particles are trans-
ferred into the small intestine where further digestion and absorption 
take place. Anatomically, the stomach is subdivided into the fundus 
which contains the cardia or esophageal orifice, the corpus and the 
more distally located antrum. 
Functionally, the stomach is traditionally divided between a prox-
imal storage compartment and a distal compartment involved in me-
chanical digestion and propulsion. The proximal stomach will actively 
relax upon food intake in the process of adaptive relaxation or gastric 
accommodation (Cannon and Lieb, 1911; Kindt and Tack, 2006). The 
temporary storage of the food in the fundus is followed by a tonic 
contraction of the proximal stomach and repetitive contractions of the 
distal stomach with the propulsion of the gastric contents against a 
closed pylorus, resulting in mixing and grinding until the particle size is 
small enough (1–2 mm) to pass through the pylorus (Kelly, 1980;  
Meyer et al., 1981). This initial phase reflects the lag time of gastric 
emptying after which emptying occurs in a linear fashion 
(Camilleri, 2006; Camilleri et al., 1985). In contrast to solids and caloric 
liquids, emptying of low- or non-caloric liquids is exponential (i.e., a 
first-order process) with a half-emptying time of approximately 15 min 
and is mainly determined by an antroduodenal pressure gradient, lar-
gely independent of antral peristaltic activity (Camilleri et al., 1985;  
Hausken et al., 2002; Indireshkumar et al., 2000; Kelly, 1980). The rate 
of gastric emptying is regulated by a duodenogastric feedback me-
chanism and is slowed down by higher caloric content, lipids and acid 
and is modulated by gut hormones (Camilleri, 2019; Dooley et al., 
1984; Heddle et al., 1988). 
Motility in the fasted state is characterized by the migrating motor 
complex (MMC), a cyclic pattern of contractions in which 4 phases have 
been defined. Phase 3 is the most active one with high-amplitude 
contractions originating from the antrum (70%) or the duodenum 
(30%) and migrating distally to the ileum in approximately 1.5 to 2 h 
(Deloose et al., 2012). Non-digestible, larger (food) remnants empty 
from the stomach during phase 3 of the MMC in the fasting state 
(Oberle et al., 1990). The parietal cells from the fundus and the corpus 
secrete hydrochloric acid (HCl) to maintain an acidic environment with 
a pH of 2–2.5 in the fasted state which rises to 4.5–6.0 immediately 
after the meal (Camilleri, 2006). 
3.1.2. Small intestine 
The small intestine functions as a vital organ for digestion and ab-
sorption of nutrients and drugs. In its latter role, small bowel motility 
patterns may modulate pharmacokinetics of ingested drugs. The small 
intestine is a large organ, ranging up to 6 m with a narrow diameter of 
approximately 2.5 cm, composed of a complex network of blood ves-
sels, nerves, and muscles located between the stomach and proximal 
colon (Kiela and Ghishan, 2016). The small intestine is comprised of 
three different regions:  
1 The duodenum is the shortest of the three sections, approximately 
30 cm in length, and has the greatest diameter (Jayaraman et al., 
2001). It connects to the stomach at the pylorus and extends to the 
ligament of Treitz or duodenojejunal flexure. The ampulla duodeni 
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major or the ampulla of Vater is located in the descending part of the 
duodenum and is the location where the common bile duct and main 
pancreatic duct join together to access the duodenal lumen. The 
sphincter of Oddi within the ampulla regulates release of bile and 
pancreatic fluids into the duodenum.  
2 The jejunum is approximately 2.5 m in length extending from the 
distal duodenum to the proximal ileum (Collins and 
Badireddy, 2019). The primary function of the jejunum is the ab-
sorption of nutrients digested in the duodenum. The jejunal surface 
contains circular folds and a mucous membrane covered in villi and 
microvilli, 0.5 – 1.6 mm in length, increasing the surface area by 30 
– 600 fold (Kiela and Ghishan, 2016). Jejunal villi are the longest 
within the small intestine.  
3 The ileum is the longest small intestine segment and extends from 
the distal jejunum to the ileocecal sphincter. Its length is approxi-
mately 3.5 m (Collins and Badireddy, 2019). The primary function 
includes absorption of lipid degradation products as well as vitamin 
B12 and bile salts (Jung et al., 2010; Tappenden, 2014). 
To summarize, the small intestine is an organ with diverse physio-
logic roles including digestion, fluid and nutrient absorption, fluid se-
cretion, and transit and dispersion of luminal contents. A more recent 
MRI study sheds light on how luminal water appears as a population of 
discontinuous liquid pockets of varying size rather than as a single, 
more static pocket (Mudie et al., 2014). All of these activities are 
important to modify luminal drug behavior throughout the GI tract 
(Fig. 1). Disruption of small intestine anatomy and/or physiology can 
have a significant impact on the overall function of the human body and 
may affect drug absorption, distribution and clearance for orally ad-
ministered drug products. 
3.2. Lower GI tract 
The colon is the distal part of the GI tract with the important 
function of absorbing water and electrolytes, vitamins, fermenting nu-
trients and store fecal content (Phillips, 1984). It consists of five parts: 
the right or ascending colon, the transverse colon, the left or descending 
colon, the sigmoid colon and the rectum. Because of the difficulties in 
accessing the entire length of the colon normally filled with feces, the 
colon has been less studied than other parts of the gut like the eso-
phagus and the stomach. However, it has been always clear that the 
transit time of the colon is physiologically slow as compared to the 
gastric emptying and the small bowel transit time and this is likely to be 
related to the fact that this long transit time is required to accommodate 
absorption, fermentation and storage. Indeed, the mean colonic transit 
time in health is about 35 h as compared to up to 3 h of the small bowel 
transit time and of up to 4 h of the gastric emptying time 
(Camilleri et al., 2008). Using scintigraphy, Abrahamsson and co- 
workers demonstrated that a colonic transit time may vary between 
10 h and 3 days, clearly showing the high (intersubject) variability 
Fig. 1. Illustrative overview of anatomical and physiological variables that affect luminal drug behavior throughout the gastrointestinal (GI) tract.  
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(Abrahamsson et al., 1996). 
For a comprehensive review of current knowledge on different co-
lonic motor patterns, their triggers and control in humans and their 
correspondence with those reported in other species, the reader is re-
ferred to the recently published first translational consensus on termi-
nology and definition of colon motility (Corsetti et al., 2019). 
The colon is thought to reabsorb around 1.5 liters of water each day 
(Kunzelmann and Mall, 2002). Until recently, it was not possible to 
assess the actual intraluminal content of free water and fluids entrapped 
in the feces. The application of MRI has demonstrated that the volumes 
of free watery fluids are typically low. The fluids are distributed in ir-
regular fluid pockets with a variable amount of 13  ±  12 mL (n = 12) 
and a range of 1 - 44 mL inside these pockets for the entire colon, 
mainly in the ascending colon (Murray et al., 2017; Schiller et al., 
2005). Very recent studies have demonstrated the possibility of also 
evaluating the actual fluidity of intracolonic content by MRI 
(Wilkinson-Smith et al., 2018). 
Physicochemical characteristics of fluids in the lower intestine, 
based on data collected with direct sampling five hours after the ad-
ministration of a glass of water to fasted healthy adults (fasted state) 
and five hours after the consumption of the high-fat, high-calorie meal 
(Food and Drug Administration 2002; European Medicines Agency 
2010) by fasted healthy adults (simulating fed state conditions) 
(Diakidou et al., 2009; Reppas et al., 2015) can be summarized as fol-
lows: in the distal ileum, the pH is approx. 8.0, regardless of the dosing 
conditions. In the proximal colon (cecum and ascending colon) the pH 
in the fasted state is about 7.8 whereas in the fed state a small drop in 
pH can be observed (pH 6.0). Buffer capacity does not differ sig-
nificantly between prandial states in the distal ileum; in the fasted state 
values are similar to those reported for the upper intestine. Compared 
to cecal and ascending colon contents, ileal contents have significantly 
lower buffer capacity only in the fed state. 
4. Aspiration of human GI fluids: Methodology 
4.1. Upper GI tract 
To sample contents from the upper GI lumen one or more catheters 
are introduced through the mouth or nose of a human volunteer 
(Fig. 2). Following the positioning of the tube(s), volunteers can ingest 
a drug formulation sometimes in combination with a solid or liquid 
meal (Rubbens et al., 2019), or, if the study requires, they can be ad-
ministered through the gastric port of the catheter directly into the 
stomach (Hens et al., 2016a; Kourentas et al., 2016). Gastric and in-
testinal fluids can subsequently be collected as a function of time, re-
sulting in a detailed GI drug concentration profile (Hens et al., 2014). 
Besides, these fluids can also be analyzed for physicochemical proper-
ties, enzyme activity and/or bile salts (Riethorst et al., 2016b). In-
testinal sampling is often combined with concomitant blood sampling 
to relate gastrointestinal drug and formulation behavior to systemic 
drug disposition (Brouwers and Augustijns, 2014). In this case, as in-
traluminal sampling inevitably includes removing a certain amount of 
drug from the intraluminal environment, the volume of aspirated 
samples should be limited (Hens et al., 2016a). 
Throughout the years, different types of catheters have been used. 
In particular, two different approaches can be applied for sampling 
studies: (i) a single catheter with multiple sampling ports (Fig. 3A) and 
(ii) multiple catheters to aspirate fluids from different segments in the 
GI tract (Fig. 3B). Depending on the nature of the study, a rational 
assessment can be made to choose the most suitable catheter. For ex-
ample, when interested in luminal concentrations at more than two 
segments of the GI tract, it can be advised to apply a single aspiration 
catheter with multiple aspiration ports which makes it less invasive for 
the volunteer and more convenient for the researcher. From a practical 
point of view, the aspiration of GI fluids occurs by placing a syringe on 
the top of the aspiration catheter and gently pulling the syringe. To 
facilitate the aspiration procedure, air can be inflated via the air 
channels. A small amount of air will be inflated via the aspiration ca-
theter to remove residual fluid residing in the aspiration channel. 
Concerning gastric aspiration studies, numerous small-scale (typi-
cally 5 to 10 healthy adult volunteers) clinical studies have been pub-
lished in which gastric drug disposition has been linked to systemic 
concentrations. Gastric sampling studies can be expanded with si-
multaneous measurements of GI motility. Intraluminal pressure waves 
can simultaneously be monitored in real-time using HRM (Meyer- 
Gerspach et al., 2018). Studies in which gastric aspirates have been 
collected without the administration of a drug product have also been 
performed and reported, even under conditions simulating the dosing 
conditions applied in oral drug absorption studies (e.g., fasted versus fed 
state) to evaluate drug dissolution or drug solubility ex vivo under 
standardized guidelines as promulgated by regulatory authorities. 
These obtained data in combination with the characterization of the 
aspirated fluids have been extremely useful for the development of 
biorelevant media (e.g., fasted/ fed state simulated gastric fluids 
(FaSSGF/ FeSSGF)) and/or the evaluation of the impact of intragastric 
drug performance on the entire absorption process (Dressman et al., 
1998). 
Regarding intestinal aspiration studies, fluids can be aspirated as 
such after administration of a glass of water (i.e., fasted state condi-
tions) or after intake of a liquid/solid meal, representing the fed state 
conditions. These aspirated fluids can, subsequently, be analyzed for 
endogenous constituents that may have a major responsibility in the 
differences in luminal drug behavior between- and within-subjects, 
explaining inter- and intra-subject differences in systemic exposure of a 
drug, respectively. Concerning drug formulation behavior in the in-
testinal tract, catheters can be positioned in the more proximal part of 
the small intestine (i.e., duodenum as depicted in Fig. 2) or more dis-
tally (e.g., jejunum) as depicted in Fig. 3. 
Exploring luminal drug behavior in the more distal parts of the 
human GI tract is from utmost interest when dealing with a delayed- or 
controlled-release drug formulation. For instance, the delayed-release 
Fig. 2. Schematic overview of the clinical aspiration technique. Left: Catheter 
(s) are introduced through the nose (A) or mouth (B) and positioned inside the 
stomach and the upper small intestine. Right: X-ray images of (A) one catheter 
positioned inside the stomach and the intestine having aspiration/ perfusion 
ports in both segments and (B) a catheter positioned inside the stomach (solid 
line) and a catheter positioned inside the intestine (dotted line); catheters are 
traced for clarity. Adapted from Vertzoni et al., 2019. Copyright Elsevier 2019. 
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properties of the amorphous solid dispersion tablet of posaconazole 
required sampling from more distal parts of the human GI tract rather 
than in the upper part (Hens et al., 2016b). It should be noted that the 
aspiration of intestinal fluids is not as easy as compared to the aspira-
tion of gastric fluids due to the limited amount of fluid volume and the 
fact that fluid has to be aspirated from the more distal parts. 
4.2. Lower GI tract 
The lower intestinal lumen cannot be reached from the mouth or the 
nose to collect intestinal contents; therefore, aspirations to date have 
been achieved during colonoscopy (Fig. 4). 
For systemically absorbed drugs, the region of interest is the distal 
ileum and ascending colon; in other regions of the colon luminal con-
ditions do not allow for adequate drug amounts to be dissolved and 
therefore transported through the mucosa. For locally acting drugs, 
however, distal regions of the large intestine are equally important. As 
mentioned before, the residual volumes in the colon are rather scarce 
which makes it difficult to adequately aspirate fluids from the different 
regions of the large intestine. In a clinical aspiration study in which 
different locally acting formulations of mesalamine were explored, 
authors aspirated fluids in the stomach, duodenum and jejunum 
(Yu et al., 2017). Fecal samples were collected to estimate the amount 
of drug molecules that reached the colon. 
5. Exploring drug product behavior in the human GI tract 
Throughout the years, numerous aspiration studies have been 
conducted to explore the luminal behavior of orally administered drug 
products. Thanks to various bilateral collaborations (e.g.,  
Psachoulias et al., 2011; Walravens et al., 2011) and multinational in-
itiatives [e.g., OrBiTo (IMI/EFPIA-funded by EU - https://www.imi. 
europa.eu/projects-results/project-factsheets/orbito), PEARRL (Marie 
Curie Action – funded by EU) and the in vivo predictive dissolution 
(iPD) project (funded by U.S. FDA)](Hens et al., 2018;2016b;  
Pentafragka et al., 2020), the sampling technique has gained a lot of 
momentum throughout the last two decades. Table 1 gives a compre-
hensive overview of different studies on how the aspiration technique 
unraveled the luminal behavior of drug products under different test 
conditions. Also, the goal of each study is highlighted. 
6. Composition of GI fluids and underlying GI physiology as a 
source of intra- & intersubject variability 
It is generally acknowledged that GI variables (e.g., motility, pH, 
fluid volumes, bile salts) affect oral formulation performance and 
consequently drug plasma levels (Abuhelwa et al., 2017). The varia-
bility of some of these parameters, as GI transit times and GI pH have 
recently been reviewed in two comprehensive meta-analyses 
(Abuhelwa et al., 2016a;2016b). Knowing the main GI determinants of 
Cmax and AUC variability will lead to the improvement of BE trial 
protocols and will guide the design of in vitro predictive dissolution tests 
incorporating the expected range of the physiological variables 
(Hens et al., 2016c). 
Boyd and colleagues recently reviewed several human intubation 
studies that attempted to characterize the in vivo dissolution process for 
poor solubility drugs (Boyd et al., 2019). As the authors stated in-
traluminal drug concentrations (i.e., dissolution rate) can be related to 
the fluid characteristics as pH, volume or composition, as a further step, 
the simultaneous monitoring of intestinal motility offers a more com-
plete picture of the product-GI environment interactions. The combined 
measurement of luminal fluid characteristics, motility patterns and lu-
minal and plasma drug concentrations is illustrated in several recent 
intubation studies performed in human volunteers, after the adminis-
tration of a solid immediate-release form of ibuprofen (Bermejo et al., 
2018; Koenigsknecht et al., 2017; Paixão et al., 2018a, 2018b), para-
cetamol (Van Den Abeele et al., 2017a), fosamprenavir 
(Braeckmans et al., 2020) and atazanavir (Hens et al., 2020). The 
ibuprofen study was performed in fasted and fed state conditions. In the 
fasted study, the glass of water for dosage administration also contained 
phenol red as a non-absorbable marker to estimate the net fluid volume 
changes. Other relevant GI co-variables as luminal pH, motility and 
buffer strength were measured. Data analysis is still ongoing but several 
outcomes have been already published. Koenigsknecht et al. described 
thoroughly the clinical study and the results were qualitatively de-
scribed, mainly pointing out the high variability of pH values across 
subjects and the effect of food on reducing ibuprofen plasma Cmax va-
lues. Interestingly, ibuprofen concentrations were still measured in the 
stomach and small intestine after 7 h which required further analysis. 
The work of Hens et al. mainly focused on the analysis of the buffer 
strength of luminal samples pointing out the much lower buffer capa-
city of luminal fluids in comparison with the common dissolution media 
and even with the so-called biorelevant media. Bermejo et al. and 
Paixao et al. applied multiple linear regression analyses to quantify the 
contribution of pH and motility indexes on plasma Cmax variability 
(Bermejo et al., 2018; Paixão et al., 2018a). With a basic mechanistic 
approach based on deconvolution from plasma levels, the relationship 
between in vivo dissolution and in vivo systemic input was explored. It 
was shown, using experimental luminal data, that in vivo luminal con-
centrations are the driving force for the intestinal permeation and, thus, 
the systemic exposure of the drug. Absorption rates estimated from 
plasma levels by deconvolution data analysis showed a good correlation 
with the in vivo dissolution, i.e., maximal absorption rates corresponded 
with the maximal luminal concentrations of ibuprofen. On the other 
Fig. 3. Fluoroscopic image of the position of a multi-channel catheter in the GI 
tract of a healthy subject. The arrows indicate the different ports present in each 
segment of the GI tract. Fluoroscopic image taken from Hens et al., 2017. 
Copyright ACS 2017. 
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hand, besides considering ibuprofen as an acidic drug (pKa ~ 4.85) 
with limited dissolution kinetics in the stomach but increased solubility 
in the small intestine, the impact of the phase III contractions post-dose 
on Cmax value was also highlighted. The longer the time to the next 
phase III after dosing the lower Cmax observed in the volunteers. Later 
on, a compartmental (stomach-duodenum-jejunum-plasma) mass 
transport analysis incorporating time to the next phase III contraction 
post-dose in each individual and their luminal pH-time profiles showed 
a well-combined fitting of luminal and plasma concentrations in several 
subjects indicating that the intersubject variability in luminal dissolu-
tion and plasma levels was highly dependent on those independent 
variables (Tsume et al., 2018). 
Related to inter-subject differences in the composition of GI fluids, 
Riethorst and co-workers characterized the duodenal aspirates of ten 
healthy subjects in fasted and fed state conditions (Riethorst et al., 
2016b). This comprehensive work highlighted the immense inter-sub-
ject variability in the endogenous constituents (e.g., bile salts, enzymes, 
lipid digestion products) present in the aspirated duodenal fluids. In a 
follow-up study, the impact of these different constituents on drug 
permeation was investigated using a fractional design of experiment 
(DoE) approach, including 16 different fluid compositions 
(Riethorst et al., 2018). Evaluating the impact of each constituent to-
wards the permeation of a drug warns us that making use of the 
‘average’ simulated biorelevant media in dissolution, solubility or 
transport experiments is not reflecting the entire picture of these dy-
namic processes in vivo. 
Unlike with gastric emptying of contents which occurs continuously 
during and after meal consumption accompanied by the so-called 
postprandial glucose fluctuations in the blood (Edinburgh et al., 2018;  
Koziolek et al., 2014; Malagelada et al., 1976), in the fed state, con-
ventional tablets and capsules must disintegrate for any undissolved 
drug to start emptying from the stomach.Aspiration studies, after the 
standard meal (Rubbens et al., 2019) confirmed earlier imaging data in 
humans (Kelly et al., 2003; Weitschies et al., 2008), according to which 
disintegration times of conventional tablets can be significantly ex-
tended when administered after the standard meal. Recent aspiration 
studies indicate that, after the disintegration of conventional dosage 
forms to solid particles, non-ionizable BCS Class I drugs empty from the 
stomach with an apparent first-order rate constant of about 40 min 
(Pentafragka et al., 2020). For non-ionizable BCS Class II drugs the 
estimated half-life for gastric emptying seems to be slightly longer, 
about 50 min (Pentafragka et al., 2020). 
The physiologic changes induced by food in the GI tract are quite 
well understood and initiate an increase in the retention time in the 
stomach, the changes in pH in the initial part of the GI tract and the 
increase of secretions that can influence solubility of drugs 
(Koziolek et al., 2019). Although the influence of these changes in the 
drug absorption process can be mechanistically interpreted, only a 
piece of direct evidence can be delivered by collecting data of the lu-
minal contents and simultaneous determination of the plasma profiles. 
This has allowed to effectively connecting the GI concentration-time 
profiles to the observed plasma profiles, as well as to elucidate some of 
the underlying physiologic sources of the observed intra- and inter- 
subject variability. In a study from the University Hospital of Michigan 
(Paixão et al., 2018a), the weak acid ibuprofen (immediate-release 
800 mg RLD tablet) was administered with a liquid meal to healthy 
subjects. After oral administration, GI fluids were aspirated and ana-
lyzed for drug content, pH and buffer capacity. In parallel, blood 
samples were also collected. Pressure events along the GI tract were 
measured to evaluate the impact of GI motility on drug product per-
formance. The authors were able to directly relate the amount of so-
luble ibuprofen in the duodenum and proximal jejunum to the rate of 
absorption of the drug as measured from the plasma profile by decon-
volution. There was a strong correlation between the amount of in-
gested calories and the duration of the fed pattern, described by the 
interval between meal administration and the return of a burst of 
rhythmic activity propagating distally, defined as a phase III event 
(tMMC-III) of the MMC. The characteristic increase of gastric pH, as 
observed by several other studies on gastric luminal physiologic beha-
vior, was confounded. Increased pH values return to fasting pH values 
over time, in particular after the tMMC-III event was observed. Inter- 
and intra-subject variability was approximately 30% for the plasma 
Cmax and 11 and 34% for the plasma AUC, respectively. When trying to 
explain this variability, it was observed that the stomach pH and an 
interaction between the stomach pH and the tMMC-III parameter were 
able to explain 63% of the observed variability in ibuprofen plasma 
Fig. 4. Schematic overview of the technique for sampling from the lumen of the lower intestine. The original picture can be accessed online in color (https://www. 
mayoclinic.org/tests-procedures/colonoscopy/about/pac-20393569, last accessed on June 3rd, 2020). 
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Cmax. This motility and pH effect was also observed in other intestinal 
aspiration studies under fed conditions. In a study of Brouwers and co- 
workers, after the oral administration of tablet of fosamprenavir (a 
phosphate ester prodrug of the poorly water-soluble HIV-inhibitor 
amprenavir), food induced a delay in the absorption of amprenavir, 
with an increase in the mean Tmax and a similar delay in the duodenal 
appearance of fosamprenavir (Brouwers et al., 2007). Although a re-
lationship between gastric pH and solubility is also expected for this 
pro-drug, the authors also proposed a formulation effect due to food- 
induced difficulties in the in vitro tablet disintegration that could also 
explain the observed delay in the duodenal appearance. This food de-
layed disintegration was also proposed to explain the delayed luminal 
gastric appearance of the solid posaconazole available as a function of 
time after the oral administration of a delayed-release formulation with 
food (Hens et al., 2016b), or a later appearance of a large amount of 
solid drug in the stomach after administration of an immediate release 
oral formulation of the weak base diclofenac (Van Den Abeele et al., 
2017c). 
Overall, these studies illustrated the importance of delayed gastric 
emptying and possible delayed disintegration, as well as the effect of 
gastric pH changes that occur with food that can eventually influence 
the dissolution of weak acids and bases. In bioavailability and bioe-
quivalence studies, food effects are usually studied under high-caloric, 
high-lipid content because these are considered to be the most dis-
criminatory conditions. However, and regarding the gastric emptying 
process, the administration of approx. 800–1000 calories (e.g., the FDA 
breakfast meal) results in a long presence of the fed state motility and 
the associated disruption of the MMC, the time point of gastric emp-
tying can be dependent on further meals and liquid intake of the sub-
jects (Koziolek et al., 2015). Since the luminal pH, secretions and col-
loidal structure changes are also observed with lower amounts of 
ingested calories, it could be questioned if the high caloric meal is in-
deed the best one to compare the performance of different formulations 
for fed state conditions. 
7. Challenges and issues 
Aspirated samples could be used for (i) quantifying drug con-
centrations, (ii) for testing the performance of active pharmaceutical 
ingredients (API) ex vivo or (iii) for developing biorelevant media. 
However, one difficulty when aiming at quantifying drug concentra-
tions is that, in contrast with the situation in the upper GI lumen, col-
lection of numerous colonic samples over time is problematic, due to 
the limited and viscous volumes available in the region (Lemmens et al., 
2020; Murray et al., 2017) and the difficulty in maintaining the colo-
noscope in place for a long period. Also, in the field of gut microbiota, it 
is extremely hard to develop a sampling method that can accurately 
quantify gut microbiota in contents collected from the lower intestine 
(Tang et al., 2020). As a result, no studies in which drug concentrations 
have been quantified in the region have been performed to date, except 
for the study performed by Lemmens and co-workers, where celecoxib 
concentrations were measured in aspirated caecal fluids after oral ad-
ministration of a 200 mg CelebrexⓇ capsule to healthy subjects 
(Lemmens et al., 2020). However, it was not feasible to aspirate nu-
merous fluids as a function of time due to the limited volume present in 
the lower GI tract. Table 2 and 3 are summarizing the potential hurdles 
that can be faced when applying the GI sampling technique to sample 
aspirates from the upper and lower GI tract, respectively. Suggestions 
towards tackling these hurdles are also provided. 
8. The collection of luminal contents from the human GI tract: 
“Best practice” 
As summarized in Table 1, GI sampling within the field of drug 
product evaluation may serve many purposes, including the exploration 
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(1) the behavior of controlled drug release delivery systems,  
(2) intestinal solubilization, supersaturation, and precipitation  
(3) food and beverages effects,  
(4) excipient(s) effects,  
(5) drug interactions (e.g., PPI),  
(6) real-life dosing conditions,  
(7) intraluminal drug stability.   
It is obvious that the design of these studies is not straightforward 
and that multiple factors need to be taken into account to allow 
justified conclusions. A careful selection of the different aspects 
related to the study design would include, among others, the se-
lection of the catheter, the positioning process (possible effect on GI 
physiology, e.g. induction of secretions), the time of drug 
administration, the time of food intake in case food effects are being 
explored, the sampling duration and frequency, the schedule of 
plasma sampling, and the type of meal (liquid versus solid, high fat 
versus low fat, high calorie versus low calorie). As explained in the 
methodology section, one can make use of two different approaches 
for sampling studies, i.e., using a single catheter or multiple cathe-
ters. The catheters used can have one or more aspiration ports. In 
addition to sampling, pressure measurements could be performed to 
monitor GI motility, either using a high-resolution manometry ca-
theter or a water-perfused motility catheter; the latter can be in-
tegrated in the sampling catheter. The selection of the catheter type 
is an important factor given the study design, but also since a ca-
theter may affect local GI physiology. Therefore, the following ca-
theter-related factors need to be taken into account: 
Table 2 
Non-exhaustive list of challenges of the GI aspiration sampling technique with respect to aspiration of fluids in the upper GI tract (i.e., stomach and small intestine).    
Issue/challenge Suggested approach, technology or cooperation  
The presence of a catheter may affect gastrointestinal (GI) physiology Reduce the diameter to the extent that aspiration of samples is still possible. 
The composition of GI fluids may change during storage. Process samples immediately after collection, for example: 
Measurement of pH and buffer capacity (limit exposure to atmospheric oxygen).  
(i) Removal of solid material (precipitated/non-dissolved drug) by filtration or centrifugation.  
(ii) Blocking in-sample drug precipitation by dilution in the organic phase.  
(iii) Inclusion of enzymatic inhibitors (including lipase inhibitors) in case digestion influences drug 
and formulation behavior (especially in fed state conditions). 
Solubility and dissolution may be affected by the presence of lipids in the 
gastrointestinal samples. 
Explore solubility and dissolution before and after separation of the lipid phase (centrifugation). 
Another possibility is to control the food intake before and during the study (e.g., controlled 
amount of lipids). 
GI sampling may reduce the amount of drug available for absorption Limit the volume and number of collected GI fluids. 
Collected gastrointestinal samples allow assessing drug concentration, not the 
amount available for absorption 
Combine GI sampling with MRI experiments to assess fluid volume. Another possibility is to 
make use of a non-absorbable marker that accounts for GI secretion, transit and dilution. 
GI motility may affect drug disposition Combine GI sampling with pressure measurements (water perfused catheter or high-resolution 
manometry). 
Different scenarios can be hypothesized: 
Acidic drugs may benefit from a fast phase 3 cycle 
Basic low-solubility compounds may benefit from a longer residence time in the stomach, 
allowing sufficient time to dissolve, possibly resulting in (higher) supersaturation upon transfer 
into the small intestine. 
Soluble compounds may be less dependent on the motility cycle (possibly traveling with the co- 
ingested water) 
GI physiology may be different in specific patient populations (e.g., pediatric 
patients, geriatric patients). 
Collect GI samples through feeding tubes or when performing endoscopic examinations. As an 
alternative, the collection and characterization of stoma fluids can be considered. Drug behavior 
can be assessed ex vivo in the collected fluids. 
Luminal concentrations may not be the driving force for absorption due to 
interaction with intraluminal compounds. 
Use of intestinal fluids in vitro assays to evaluate the bio-accessible fraction. Combine with: 
Dialysis experiments, cell-based or cell-free permeation assays. 
The position and activity status of the volunteer/patient may affect 
gastrointestinal drug disposition (also applicable to MRI studies). 
Explore the influence of lying versus supine position versus walking on GI drug distribution. 
Standardize position/activity as much as possible. 
Equilibrium solubility studies are performed in the absence of bicarbonates 
(eliminated during equilibration). 
Measure initial and equilibrium pH to evaluate the importance. 
Table 3 
Non-exhaustive list of challenges of the GI aspiration sampling technique concerning the aspiration of fluids in the lower GI tract (i.e., large intestine).    
Issue/challenge Suggested approach, technology or cooperation  
Colonic fluids are difficult to collect and are viscous, two factors impeding time- 
dependent assessment of luminal drug concentration in the colon. 
Assess drug concentrations in biopsies of colonic tissue collected as a function of time as 
an indirect reflection of luminal concentrations (equilibrium versus non-equilibrium 
conditions) 
GI physiology may be affected by the disease state (e.g., Crohn's disease, ulcerative 
colitis) 
Assess drug concentrations in biopsies of colonic tissue as an indirect reflection of 
luminal concentrations. Compare concentrations in diseased with those in non-diseased 
tissue 
Include information on the inflammation status 
The cleaning procedure (enema, bisacodyl, rinsing of the lens) before colonic sample 
collection may alter the composition and drug concentration of luminal samples. 
Limit enema to left hemicolon and sample from the undisturbed right hemicolon. 
Apply a validated, colon preparation protocol which involves the administration of light 
laxative (bisacodyl) at least approximately 2 days before colonoscopy (Diakidou et al., 
2009). 
Luminal concentrations may not be the driving force for absorption due to interaction 
with intraluminal compounds. 
Use of intestinal fluids in vitro assays to evaluate the bio-accessible fraction. The 
combination can be made with dialysis experiments, cell-based or cell-free permeation 
assays. 
There is no certain measure to evaluate locally acting drug products. The collection of fecal samples may be a good surrogate tool to assess the clinical 
importance of bacterial drug degradation in the distal ileum and proximal colon 
(Vertzoni et al., 2018). In addition, gamma scintigraphy can trace the locally-acting 
product (radio-labeled). 
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(1) the diameter of the catheter(s),  
(2) the length of the catheter (depending on whether samples will be 
collected from the stomach, duodenum, or jejunum; when targeting 
the jejunum, the presence of an inflatable balloon may facilitate 
transit of the catheter),  
(3) the material used (polyvinyl chloride, silicone, …),  
(4) the need to simultaneously measure pressure events,  
(5) single-use versus reusable catheters (multiple uses requiring a 
careful cleaning and disinfection procedure). 
It should be noted that studies using catheters placed inside the GI 
tract are inherently invasive and can, thus, potentially affect normal GI 
physiology. Several studies indicate minor or non-significant effects of 
thin and pliable transpyloric tubes on gastric emptying, gastric secre-
tions and duodenal-gastric reflux (Müller-Lissner et al., 1983, 1982). 
However, comparative studies should be performed in parallel to con-
firm the same results for other types of catheters. It is thus important to 
carefully consider the selection of the catheter, always keeping in mind 
that a simple design will have fewer effects on local physiology. One 
can partly compensate for this effect on physiology by performing 
comparative studies using the same catheter. Related to the diameter of 
the catheter used, numerous studies have been performed. Longstreth 
et al. have shown that a 4 mm outside diameter (OD) transpyloric tube 
does not significantly affect gastric emptying of contents after admin-
istration of a meal (Longstreth et al., 1975). Mueller-Lissner et al. 
(Müller-Lissner et al., 1982) showed similar data for a 5 mm OD, after 
administration of liquid meals, unlike the situation where more than 
one tube is passing through the pylorus (Read et al., 1983). 
All aspects mentioned so far need to be carefully considered as they 
may all have an impact on the overall outcome. It is therefore obvious 
that a single standard procedure for the collection of intestinal fluids is 
not possible. Careful consideration of all conditions is required, so that 
justified decisions can be made depending on the study objectives. As 
an example of an intestinal sampling technique, a protocol is presented 
in line with the bioavailability (BA) and bioequivalence (BE) guidelines 
as promulgated by the US FDA, entitled ‘Food-Effect Bioavailability and 
Fed Bioequivalence Studies’ (U.S. Food and Drug Administration, 
2017). Related to exploring food effects, regulatory guidelines that 
provide a protocol to perform clinical pharmacokinetic studies in fasted 
and fed state conditions can be considered. 
The reasoning so far especially relates to the collection of samples 
from the upper GI tract; given the limited amount of fluids in the colon, 
it is presently not feasible to collect colonic fluids as a function of time 
to monitor formulation performance. 
8.1. Upper GI tract 
8.1.1. Fasted and fed state studies 
Numerous actions should be considered to perform state-of-the-art 
aspiration studies in fasted and fed state conditions.  
1 Before the start of the study, an overnight fast of at least 12 h should 
be respected. Water can be allowed as desired except for one hour 
before drug administration  
2 After the overnight fast, subjects come to the hospital in the morning 
and are intubated with the GI catheter(s). The positioning of the 
catheter(s) in the region of interest should be checked and con-
firmed (e.g., fluoroscopy). Note that female participants need to be 
screened for pregnancy (i.e., exclusion criteria).  
3 After positioning of the catheter(s), the subject needs to be located 
in an upright supine position to make it feasible for the researcher to 
aspirate the fluids and, if intended, to take blood samples. 
4 After a stabilization period of 30 min (to assure that excessive se-
cretions in the stomach during the insertion of the tube and during 
the stabilization period have been eliminated), the subject will be 
asked to ingest the formulation product with 240 mL of water. 
Depending on the goal of the study, the co-administered beverage 
can change in terms of (i) the nature of the drink and (ii) the vo-
lume. In the case of fed state studies, subjects should start with the 
recommended meal 30 min before the administration of the drug 
product. The volunteers should consume this meal in 30 min or less; 
however, the drug product should be administered 30 min after the 
start of the meal. The subject will be asked to ingest the formulation 
product with 240 mL of water 30 min after the start of the intake of 
the meal. No food should be allowed for at least 4 h post-dose. Water 
can be allowed as desired except for one hour after drug adminis-
tration. Subjects should receive standardized test meals at the same 
time in each period of the study. For the test meal, a high-fat (ap-
prox. 50 percent of the total caloric content of the meal) and high- 
calorie (approximately 800 to 1000 calories) solid or liquid meal is 
recommended. This test meal should derive approximately 150, 
250, and 500–600 calories from protein, carbohydrate, and fat, re-
spectively.  
5 For both fasted and fed state treatment periods, timed samples of 
biological fluid (i.e., GI fluids and/or plasma), should be collected 
from the subjects to permit characterization of the complete shape 
of the GI/ plasma concentration-time profile for the parent drug. It 
may be advisable to measure other moieties in the biological fluid, 
including active metabolites. Fluid samples will be aspirated by 
using a syringe. After the collection of the aspirated fluid, fluids will 
be further handled as discussed in the next section. Note that only a 
limited volume of fluid should be collected to safeguard the dynamic 
environment as good as possible. Afterwards, a small amount of air 
will be inflated via the aspiration catheter to remove residual fluid 
residing in the aspiration channel.  
6 When the complete shape of the GI concentration-time profile(s) is 
captured, the GI catheters can be removed. 
8.2. Lower GI tract 
For the aspiration of fluids from the lower GI tract, we still face a 
hurdle concerning the limited and viscous amounts available for as-
piration as mentioned in the section ‘Challenges and issues’. MRI stu-
dies highlighted the low amount of freely mobile water in the fasted 
human colon which was in the order of only a few milliliters 
(Murray et al., 2017; Schiller et al., 2005). Collection of samples of 
colonic contents, is feasible (Diakidou et al., 2009; Reppas et al., 2015;  
Vertzoni et al., 2010b) and useful for measuring drug solubility and 
preparing biorelevant media (Vertzoni et al., 2010a). In those studies, 
subject work-up involved the administration of 10 mg of bisacodyl 50 h 
before colonoscopy plus 10 mg of bisacodyl 44 h before each colono-
scopy. With this regimen, bisacodyl effects on the intracolonic en-
vironment at the time of colonoscopy are eliminated (Diakidou et al., 
2009) and collected volumes were similar to those previously observed 
with MRI studies (Schiller et al., 2005). A recent study demonstrated 
the colonic disposition of celecoxib in healthy subjects after intake of a 
200 mg dose (Lemmens et al., 2020). In this study, the colon prepara-
tion procedure existed in a one-time enema of 250 mL of water to 
cleanse the left hemicolon, while avoiding spill over to the right 
hemicolon where then physiologically relevant samples could be col-
lected. During two separate moments (approx. 2.5 h and 7.5 h after 
intake of the drug product), caecal content was aspirated and analyzed 
for celecoxib and its carboxy metabolite. Celecoxib was only ex-
tensively present in the samples collected during the second aspiration 
moment. However, it should be noted that it was not feasible to aspirate 
samples as a function of time in the context of formulation evaluation in 
the lower intestine. 
8.3. Sample handling of the GI fluids upon collection 
Following the collection of GI fluids, samples should be handled 
properly to generate reliable results that reflect the local intraluminal 
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situation. This is usually very challenging and difficult to perform given 
the rapidly changing conditions upon sample collection: the sample is 
disconnected from its physiological environment, biochemical pro-
cesses proceed, and the drug present in the sample may continue to 
dissolve, precipitate (in case of supersaturation), or degrade. All these 
challenges need to be considered when performing intestinal sampling 
experiments. 
An important factor which relates to physiological conditions is the 
pH of the aspirated fluids: because of the loss of endogenous CO2 pre-
sent in the sample, the pH should be measured immediately upon col-
lection to guarantee a representative pH value; the same applies if 
buffer capacity is being explored: in fasted state conditions, it should be 
determined immediately (Litou et al., 2020), while it is less critical in 
fed state conditions, as, in these conditions, pH may be governed by 
food compounds (or its degradation) products. In case pH may affect 
the solubility of a drug (pKa within pH range interval), immediate 
processing of the sample is required when product performance is being 
assessed to exclude a time dependent pH effect. Prompt sample hand-
ling is also required when intestinal samples are collected when su-
persaturated concentrations are expected in the intestinal environment, 
either following the GI pH shift (e.g., transfer from a basic drug dis-
solved in the acidic environment to the neutral environment of the 
small intestine) or based on an enabling formulation approach. It is 
obvious that, in case of supersaturation, samples should be centrifuged 
or filtered immediately upon collection, and that the supernatant 
should be diluted in a medium which prevents further precipitation 
(e.g., containing a sufficient amount of organic solvent). To determine 
solution concentrations of the drug, aspirates need to be centrifuged/ 
filtrated immediately. Subsequently, the supernatant/filtrate needs to 
be diluted with, for example, an organic solvent that has a high solu-
bilizing capacity concerning the drug compound (to avoid any pre-
cipitation/stability issues). Total concentrations can be determined by 
immediately (i.e., no centrifugation/filtration step) diluting a with-
drawn sample with an organic solvent to capture dissolved and un-
dissolved drug. The thermodynamic solubility of the drug can be de-
termined by the shake-flask method, incubating the intestinal fluid 
samples for a minimal time (i.e., until the equilibrium solubility is 
reached) with an excess amount of the drug API at 37 °C. After a 
minimum period of shaking (to be determined), the fluids need be 
centrifuged/filtrated and the supernatant/filtrate should be diluted 
with an organic solvent, before bioanalysis. 
In case the drug is prone to enzymatic or chemical degradation, 
stabilizing conditions need to be created, for instance by a reduced 
temperature (put the sample immediately on ice until further proces-
sing), the inclusion of chemically stabilizing agents (e.g., antioxidants), 
or by the inclusion of (a) specific enzyme-inhibitor(s) in the case of 
prodrugs or enzymatically-sensitive drug molecules are involved. Based 
on the reasoning so far, it is obvious that a single standard procedure of 
sample handling cannot be developed; the multifaceted issues necessi-
tate a careful design of collection conditions and processing of samples 
to produce reliable/reproducible results when using the intestinal 
sampling technique. 
9. Conclusion and future perspectives 
In conclusion, this comprehensive review aimed to highlight the 
aspiration technique as an important in vivo tool to evaluate luminal 
drug and formulation behavior in the human GI tract. With a history of 
more than a century, the technique has evolved over the years and the 
combination with additional techniques is being considered (e.g., lu-
minal sampling in combination with recording gastric motility). Since 
not all physiological variables can be measured during a clinical as-
piration study at the same time, researchers are intensively collabor-
ating to explore which techniques can be combined to measure multiple 
GI variables simultaneously. 
Not only can the aspiration technique assist people in academics 
and the pharmaceutical industry to use the obtained data as a reference 
to optimize their in-house in vitro and in silico models, provide new 
knowledge for improved oral dosage forms and drug delivery innova-
tions, the aspiration technique can also be a valuable tool to assist 
physicians in unraveling clinical issues in specific patient populations. 
Concerning the upper GI tract, it remains unclear how drugs will be 
presented to the intestinal membrane in patients after bariatric surgery 
(Roux-en-Y gastric bypass or sleeve gastrectomy) or an upper GI stoma 
(ileostomy or jejunostomy). As important physiological variables can be 
altered (e.g., transit times, secretion rates, pH) compared to healthy 
subjects, the knowledge of how and to what extent orally administered 
drugs will be absorbed in this population is largely lacking. The as-
piration technique can be used to aspirate GI fluids in these populations 
to monitor drug and formulation behavior in the regions of interest. 
Concerning the lower GI tract, it is of great importance that the anti- 
inflammatory drugs (e.g., mesalazine) reach the site of inflammation in 
the case of patients suffering from, for example, ulcerative colitis. 
Different formulations are available but it is unclear whether they all 
deliver sufficient drug levels at the desired site consistently, as they 
may not disperse appropriately under both active and quiescent periods 
of the disease. Nevertheless, safety and efficacy should be guaranteed 
during clinical phase studies prior to the marketing authorization of the 
drug product. These insights can assist in future drug development. 
However, it is questionable if the aspiration technique can fully resolve 
these specific questions as it is extremely difficult to position the ca-
theter in a non-cleaned/prepared colon, containing almost no residual 
fluids to aspirate. Thus, ‘formulation evaluation’ in the lower intestine 
remains extremely challenging when applying the sampling technique. 
However, ex vivo evaluation of drug solubility in colonic aspirates is 
feasible (Vertzoni et al., 2010a) be pushed forward where colonic 
content can be applied concerning solubility and permeability experi-
ments. On the other hand, the aspiration technique could be applied to 
deliver drugs in specific regions (conform to the Loc-I-GutⓇ Loc-I-Col 
methods) of the colon and see how this is linked to a pharmacodynamic 
effect (PK/PD study) (Lennernäs et al., 1995; Tannergren et al., 2009;  
Zhang et al., 2015). 
As most of the studies described in this review were based on the 
recruitment of healthy subjects, there is a shift towards exploring the 
sampling technique in patient populations (e.g., UC (Vertzoni et al., 
2010b), Crohn's disease (Vertzoni et al., 2020), bariatric surgery) 
nowadays (Carlson et al., 2002). There is, indeed, definitely a need to 
use the aspiration technique in specific patient populations to better 
understand the impact of altered GI physiology on the luminal and 
systemic behavior of a drug and make the comparison between healthy 
and patient populations. When these differences can be mapped, for-
mulation scientist can develop drug products for specific patient po-
pulations with a more rational and scientific approach, instead of 
hoping-for-the-best. In the end, this will result in time- and cost-effec-
tive research which is a benefit for pharmaceutical companies and, in 
the end, patients. 
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